Citations (259)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (46)
Simone Perna, Manuela Mainardi, Paolo Astrone, Carlotta Gozzer, Anna Biava, Ruben Bacchio, Daniele Spadaccini, Sebastiano Bruno Solerte & Mariangela Rondanelli. (2018) 12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus. Clinical Pharmacology: Advances and Applications 10, pages 141-151.
Read now
Read now
Tatsuya Atsumi, Yoshiaki Ando, Shinichi Matsuda, Shiho Tomizawa, Riwa Tanaka, Nobuhiro Takagi & Ayako Nakasone. (2018) Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database. Modern Rheumatology 28:3, pages 435-443.
Read now
Read now
Holly E Gurgle, Karen White & Carrie McAdam-Marx. (2016) SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives. Vascular Health and Risk Management 12, pages 239-249.
Read now
Read now
Christian Leporini, Rosanna Piro, Francesco Ursini, Francesca Maida, Caterina Palleria, Franco Arturi, Maria Pavia, Giovambattista De Sarro & Emilio Russo. (2016) Monitoring safety and use of old and new treatment options for type 2 diabetic patients: a two-year (2013–2016) analysis. Expert Opinion on Drug Safety 15:sup2, pages 17-34.
Read now
Read now
Marc Evans, Stephen C. Bain & Jiten Vora. (2016) A systematic review of the safety of incretin-based therapies in type 2 diabetes. Expert Review of Endocrinology & Metabolism 11:2, pages 217-232.
Read now
Read now
Wuquan Deng, Sheng Qiu, Gangyi Yang & Bing Chen. (2015) Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives. Therapeutics and Clinical Risk Management 11, pages 1153-1162.
Read now
Read now
Leigh MacConell, Kate Gurney, Jaret Malloy, Ming Zhou & Orville Kolterman. (2015) Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients. Diabetes, Metabolic Syndrome and Obesity 8, pages 241-253.
Read now
Read now
André J Scheen. (2015) Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety 14:4, pages 505-524.
Read now
Read now
Agostino Consoli & Gloria Formoso. (2015) Potential side effects to GLP-1 agonists: understanding their safety and tolerability. Expert Opinion on Drug Safety 14:2, pages 207-218.
Read now
Read now
Meng-Wong Taing, Felicity J Rose & Jonathan P Whitehead. (2014) GLP-1(28-36)amide, the Glucagon-like peptide-1 metabolite: friend, foe, or pharmacological folly?. Drug Design, Development and Therapy 8, pages 677-688.
Read now
Read now
Elizabeth A. Suarez, Carol E. Koro, Jennifer B. Christian, Alicia D. Spector, Andre B. Araujo & Sybil Abraham. (2014) Incretin-mimetic therapies and pancreatic disease: a review of observational data. Current Medical Research and Opinion 30:12, pages 2471-2481.
Read now
Read now
Jocelyn de Heer & Burkhard Göke. (2014) Are incretin mimetics and enhancers linked to pancreatitis and malignant transformations in pancreas?. Expert Opinion on Drug Safety 13:11, pages 1469-1481.
Read now
Read now
Brian K Irons & Molly G Minze. (2014) Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes, Metabolic Syndrome and Obesity 7, pages 15-24.
Read now
Read now
Louis Kuritzky, Guillermo Umpierrez, Jean Marie Ekoé, Leonardo Mancillas-Adame & Laura Fernández Landó. (2014) Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes. Postgraduate Medicine 126:6, pages 60-71.
Read now
Read now
Theodosios D Filippatos, Vasilios G Athyros & Moses S Elisaf. (2014) The pharmacokinetic considerations and adverse effects of DDP-4 inhibitors. Expert Opinion on Drug Metabolism & Toxicology 10:6, pages 787-812.
Read now
Read now
Yutaka Seino, Nobuya Inagaki, Hajime Miyahara, Inaha Okuda, Mark Bush, June Ye, M. Claire Holland, Susan Johnson, Eric Lewis & Hiromu Nakajima. (2014) A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Current Medical Research and Opinion 30:6, pages 1095-1106.
Read now
Read now
Stanley Schwartz. (2014) Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes. Postgraduate Medicine 126:3, pages 66-84.
Read now
Read now
John Gerich. (2013) Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. International Journal of General Medicine 6, pages 877-895.
Read now
Read now
David D. Dore, Mohamed Hussein, Clorinda Hoffman, Elise M. Pelletier, Daniel B. Smith & John D. Seeger. (2013) A pooled analysis of exenatide use and risk of acute pancreatitis. Current Medical Research and Opinion 29:12, pages 1577-1586.
Read now
Read now
Mark W Stolar, Michael Grimm & Steve Chen. (2013) Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 6, pages 435-444.
Read now
Read now
Carolyn F Deacon & Jens J Holst. (2013) Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Expert Opinion on Pharmacotherapy 14:15, pages 2047-2058.
Read now
Read now
Andre Scheen. (2013) Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opinion on Drug Safety 12:4, pages 545-557.
Read now
Read now
Jaime A. Davidson, Carla Nikkei & Michael Grimm. (2013) Exenatide Once Weekly: Opportunities in the Primary Care Setting. Postgraduate Medicine 125:3, pages 68-78.
Read now
Read now
David G Parkes, Kenneth F Mace & Michael E Trautmann. (2013) Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opinion on Drug Discovery 8:2, pages 219-244.
Read now
Read now
Bo Ahrén. (2013) Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors. European Diabetes Nursing 10:1, pages 31-36.
Read now
Read now
Shamsa Ali & Vivian Fonseca. (2013)
Saxagliptin overview: special focus on safety and adverse effects. Expert Opinion on Drug Safety 12:1, pages 103-109.
Read now
Read now
Leigh MacConell, Carl Brown, Kate Gurney & Jenny Han. (2012) Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes, Metabolic Syndrome and Obesity 5, pages 29-41.
Read now
Read now
Johan Jendle, Sherry A Martin & Zvonko Milicevic. (2012) Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. Expert Opinion on Investigational Drugs 21:10, pages 1463-1474.
Read now
Read now
Eduard Montanya. (2012) A comparison of currently available GLP-1 receptor agonists for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy 13:10, pages 1451-1467.
Read now
Read now
Gregory Peterson. (2012) Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?. Annals of Medicine 44:4, pages 338-349.
Read now
Read now
Devesh Sennik, Fahad Ahmed & David Russell-Jones. (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes. Expert Review of Endocrinology & Metabolism 7:1, pages 15-26.
Read now
Read now
André J Scheen. (2012) A review of gliptins in 2011. Expert Opinion on Pharmacotherapy 13:1, pages 81-99.
Read now
Read now
Franco Folli & Rodolfo Guardado Mendoza. (2011) Potential use of exenatide for the treatment of obesity. Expert Opinion on Investigational Drugs 20:12, pages 1717-1722.
Read now
Read now
Javier Morales. (2011) The Pharmacologic Basis for Clinical Differences among GLP-1 Receptor Agonists and DPP-4 Inhibitors. Postgraduate Medicine 123:6, pages 189-201.
Read now
Read now
Vanita R. Aroda & Mary Beth DeYoung. (2011) Clinical Implications of Exenatide as a Twice-Daily or Once-Weekly Therapy for Type 2 Diabetes. Postgraduate Medicine 123:5, pages 228-238.
Read now
Read now
Lindsay A Bischoff, Serge A Jabbour & Jeffrey L Miller. (2011) Exenatide once weekly in type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 12:8, pages 1297-1303.
Read now
Read now
Paul S. Jellinger. (2011) Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes. Postgraduate Medicine 123:1, pages 53-65.
Read now
Read now
Mansur Shomali. (2011) Add-on therapies to metformin for type 2 diabetes. Expert Opinion on Pharmacotherapy 12:1, pages 47-62.
Read now
Read now
Biju Jose, Abd A Tahrani, Milan K Piya & Anthony H Barnett. (2010) Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Preference and Adherence 4, pages 313-324.
Read now
Read now
Mary Elizabeth Cox, Jennifer Rowell, Leonor Corsino & Jennifer B Green. (2010) Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. Drug, Healthcare and Patient Safety 2, pages 7-19.
Read now
Read now
Bo Ahrén. (2010) Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. Diabetes, Metabolic Syndrome and Obesity 3, pages 31-41.
Read now
Read now
Karen Barnard, Mary Elizabeth Cox & Jennifer B Green. (2010) Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 3, pages 363-372.
Read now
Read now
Michael A Valentino, Francheska Colon-Gonzalez, Jieru E Lin & Scott A Waldman. (2010) Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. Expert Review of Endocrinology & Metabolism 5:5, pages 765-783.
Read now
Read now
Jeff Unger & Christopher G. Parkin. (2010) Type 2 Diabetes: An Expanded View of Pathophysiology and Therapy. Postgraduate Medicine 122:3, pages 145-157.
Read now
Read now
Kristen M Kulasa & Robert R Henry. (2009) Pharmacotherapy of hyperglycemia. Expert Opinion on Pharmacotherapy 10:15, pages 2415-2432.
Read now
Read now
Bruce Bode & Alpesh Amin. (2009) Incretin-Based Therapies: Review of the Outpatient Literature with Implications for Use in the Hospital and After Discharge. Hospital Practice 37:1, pages 7-21.
Read now
Read now
Articles from other publishers (213)
Mia Aakjær, Marie Louise De Bruin & Morten Andersen. (2023) Epidemiological surveillance of drug safety using cumulative sequential analysis in electronic healthcare data. Basic & Clinical Pharmacology & Toxicology.
Crossref
Crossref
Aschner Pablo, Blanc Evelyn, Folino Claudia & Morosán A. Yanina. (2021) GLP-1RA and SGLT2i: Cardiovascular Impact on Diabetic Patients. Current Hypertension Reviews 17:2, pages 149-158.
Crossref
Crossref
Lotte Bjerre Knudsen. (2019) Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity. ACS Pharmacology & Translational Science 2:6, pages 468-484.
Crossref
Crossref
Eric Nolen-Doerr, Mary-Catherine Stockman & Ivania Rizo. (2019) Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity. Current Obesity Reports 8:3, pages 284-291.
Crossref
Crossref
Donnie Funch, Kathleen Mortimer, Najat J. Ziyadeh, John D. Seeger, Ling Li, Heather Norman, Atheline Major‐Pedersen, Heidrun Bosch‐Traberg, Helge Gydesen & David D. Dore. (2019) Liraglutide use and evaluation of pancreatic outcomes in a US commercially insured population. Diabetes, Obesity and Metabolism 21:8, pages 1837-1848.
Crossref
Crossref
Marion L. Vetter, Kristina Johnsson, Elise Hardy, Hui Wang & Nayyar Iqbal. (2019) Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials. Diabetes Therapy 10:4, pages 1249-1270.
Crossref
Crossref
Andrew Bate, Ken Hornbuckle, Juhaeri Juhaeri, Stephen P. Motsko & Robert F. Reynolds. (2019) Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Therapeutic Advances in Drug Safety 10, pages 204209861986474.
Crossref
Crossref
John-Michael Gamble, Jennifer R. Donnan, Eugene Chibrikov, Laurie K. Twells, William K. Midodzi & Sumit R. Majumdar. (2018) Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes. Scientific Reports 8:1.
Crossref
Crossref
Jin-Liern Hong, John B. Buse, Michele Jonsson Funk, Virginia Pate & Til Stürmer. (2018) The Risk of Acute Pancreatitis After Initiation of Dipeptidyl Peptidase 4 Inhibitors: Testing a Hypothesis of Subgroup Differences in Older U.S. Adults. Diabetes Care 41:6, pages 1196-1203.
Crossref
Crossref
Angelo Avogaro, Elías Delgado & Ildiko Lingvay. (2018) When metformin is not enough: Pros and cons of SGLT2 and DPP‐4 inhibitors as a second line therapy. Diabetes/Metabolism Research and Reviews 34:4.
Crossref
Crossref
Carol Koro, Janet Pientka, Veronica Bainbridge, Natalie O’Donnell, Monika Stender & Annette Stemhagen. (2017) Quantitative Testing of Prescriber Knowledge Regarding the Risks and Safe Use of Albiglutide. Drugs - Real World Outcomes 5:1, pages 55-67.
Crossref
Crossref
Yutaka Seino, Yasuo Terauchi, Takeshi Osonoi, Daisuke Yabe, Nobuyuki Abe, Tomoyuki Nishida, Jeppe Zacho & Shizuka Kaneko. (2017)
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in
J
apanese people with type 2 diabetes
. Diabetes, Obesity and Metabolism 20:2, pages 378-388.
Crossref
Crossref
Xingcheng Wu, Jia Zhu, Danyang Xiao, Xueqin Lin & Rui Ding. (2017) GA-ADE: a novel approach based on graph algorithm to improves the detection of adverse drug events. Multimedia Tools and Applications 77:3, pages 3493-3507.
Crossref
Crossref
. 2018. Post-Authorization Safety Studies of Medicinal Products. Post-Authorization Safety Studies of Medicinal Products
49
103
.
Yeon Suk Kim & Jae Hee Cho. (2017) Drug Induced Acute Pancreatitis. The Korean Journal of Pancreas and Biliary Tract 22:4, pages 153-157.
Crossref
Crossref
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti & Edoardo Mannucci. (2017)
Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis):
D
ata from randomized controlled trials
. Diabetes, Obesity and Metabolism 19:9, pages 1233-1241.
Crossref
Crossref
Michael A. Nauck, Jean-Louis Frossard, Jamie S. Barkin, Greg Anglin, Ingrid E. Hensley, Kristine D. Harper & Zvonko Milicevic. (2017) Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide. Diabetes Care 40:5, pages 647-654.
Crossref
Crossref
Masanori Emoto, Tomonori Oura, Akiko Matsui, Hirotaka Kazama & Noriyuki Iwamoto. (2017) Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials. Endocrine Journal 64:2, pages 191-206.
Crossref
Crossref
Rainer Winnenburg & Nigam H. Shah. (2016) Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature. BMC Bioinformatics 17:1.
Crossref
Crossref
Zaizhong Ni, Bin Wang, Xiaofeng Ma, Huikun Duan, Pingzhe Jiang, Xiaodan Li, Qian Wei, Xiangzhen Ji & Minggang Li. (2016) Toxicology Assessment of a Dual-Function Peptide 5rolGLP-HV in Mice. Applied Biochemistry and Biotechnology 180:7, pages 1276-1285.
Crossref
Crossref
Antoni F. Z. Wisniewski, Andrew Bate, Cedric Bousquet, Andreas Brueckner, Gianmario Candore, Kristina Juhlin, Miguel A. Macia-Martinez, Katrin Manlik, Naashika Quarcoo, Suzie Seabroke, Jim Slattery, Harry Southworth, Bharat Thakrar, Phil Tregunno, Lionel Van Holle, Michael Kayser & G. Niklas Norén. (2016) Good Signal Detection Practices: Evidence from IMI PROTECT. Drug Safety 39:6, pages 469-490.
Crossref
Crossref
Hui Peng, Laura L. Want & Vanita R. Aroda. (2016) Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program. Current Diabetes Reports 16:5.
Crossref
Crossref
Yanan HouStephen A. Ernst, Kaeli HeidenreichJohn A. Williams. (2016) Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. American Journal of Physiology-Gastrointestinal and Liver Physiology 310:1, pages G26-G33.
Crossref
Crossref
Chris E. Forsmark. (2016) Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know. Pancreatology 16:1, pages 10-13.
Crossref
Crossref
Liberata Sportiello, Concetta Rafaniello, Cristina Scavone, Cristiana Vitale, Francesco Rossi & Annalisa Capuano. (2016) The importance of Pharmacovigilance for the drug safety: Focus on cardiovascular profile of incretin-based therapy. International Journal of Cardiology 202, pages 731-735.
Crossref
Crossref
Kuan-Fu Liao, Cheng-Li Lin, Shih-Wei Lai & Wen-Chi Chen. (2016) Sitagliptin use and risk of acute pancreatitis in type 2 diabetes mellitus: A population-based case-control study in Taiwan. European Journal of Internal Medicine 27, pages 76-79.
Crossref
Crossref
R. Sekar, K. Singh, A.W.R. Arokiaraj & B.K.C. Chow. 2016.
279
341
.
Juan M. Banda, Alison Callahan, Rainer Winnenburg, Howard R. Strasberg, Aurel Cami, Ben Y. Reis, Santiago Vilar, George Hripcsak, Michel Dumontier & Nigam Haresh Shah. (2015) Feasibility of Prioritizing Drug–Drug-Event Associations Found in Electronic Health Records. Drug Safety 39:1, pages 45-57.
Crossref
Crossref
M Elle Saine, Dena M Carbonari, Craig W Newcomb, Melissa S Nezamzadeh, Kevin Haynes, Jason A Roy, Serena Cardillo, Sean Hennessy, Crystal N Holick, Daina B Esposito, Arlene M Gallagher, Harshvinder Bhullar, Brian L Strom & Vincent Lo ReIIIIII. (2015) Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs. BMC Pharmacology and Toxicology 16:1.
Crossref
Crossref
Amy Usborne, Richard A. Byrd, James Meehan, Jamie L. Blackbourne, John Sullivan, Florence Poitout-Belissent, Annick Prefontaine, Jennifer A. Martin & John L. Vahle. (2015) An Investigative Study of Pancreatic Exocrine Biomarkers, Histology, and Histomorphometry in Male Zucker Diabetic Fatty (ZDF) Rats Given Dulaglutide by Subcutaneous Injection Twice Weekly for 13 Weeks. Toxicologic Pathology 43:8, pages 1093-1102.
Crossref
Crossref
Paul T. Fanta & Andrew M. Lowy. 2015. Yamada' s Textbook of Gastroenterology. Yamada' s Textbook of Gastroenterology
1761
1781
.
John L. Vahle, Richard A. Byrd, Jamie L. Blackbourne, Jennifer A. Martin, Steven D. Sorden, Thomas Ryan, Thomas Pienkowski, Thomas J. Rosol, Paul W. Snyder & Günter Klöppel. (2015) Effects of the GLP-1 Receptor Agonist Dulaglutide on the Structure of the Exocrine Pancreas of Cynomolgus Monkeys. Toxicologic Pathology 43:7, pages 1004-1014.
Crossref
Crossref
Annachiara Uccellatore, Stefano Genovese, Ilaria Dicembrini, Edoardo Mannucci & Antonio Ceriello. (2015) Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Therapy 6:3, pages 239-256.
Crossref
Crossref
CJ Bailey. (2015) Safety of antidiabetes medications: An update. Clinical Pharmacology & Therapeutics 98:2, pages 185-195.
Crossref
Crossref
Johannes Werzowa, Marcus Säemann, Michael Haidinger, Michael Krebs & Manfred Hecking. (2015) Antidiabetic therapy in post kidney transplantation diabetes mellitus. Transplantation Reviews 29:3, pages 145-153.
Crossref
Crossref
Laurent Azoulay. (2015) Incretin-Based Drugs and Adverse Pancreatic Events: Almost a Decade Later and Uncertainty Remains. Diabetes Care 38:6, pages 951-953.
Crossref
Crossref
Reimar Wernich Thomsen, Lars Pedersen, Niels Møller, Johnny Kahlert, Henning Beck-Nielsen & Henrik Toft Sørensen. (2015) Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 38:6, pages 1089-1098.
Crossref
Crossref
Yun-Xi Liu, Mei-Mei Si, Wei Lu, Li-Xia Zhang, Chang-Xin Zhou, Shu-Li Deng & Hao-Shu Wu. (2015) Effects and molecular mechanisms of the antidiabetic fraction of Acorus calamus L. on GLP-1 expression and secretion in vivo and in vitro. Journal of Ethnopharmacology 166, pages 168-175.
Crossref
Crossref
Davide Soranna, Cristina Bosetti, Manuela Casula, Elena Tragni, Alberico L. Catapano, Carlo La Vecchia, Luca Merlino & Giovanni Corrao. (2015) Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database. Diabetes Research and Clinical Practice 108:2, pages 243-249.
Crossref
Crossref
K. K. Clemens, E. McArthur, J. L. Fleet, I. Hramiak & A. X. Garg. (2015) The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort study. CMAJ Open 3:2, pages E172-E181.
Crossref
Crossref
Yehuda Handelsman, Zachary T. Bloomgarden, George Grunberger, Guillermo Umpierrez, Robert S. Zimmerman, Timothy S. Bailey, Lawrence Blonde, George A. Bray, A. Jay Cohen, Samuel Dagogo-Jack, Jaime A. Davidson, Daniel Einhorn, Om P. Ganda, Alan J. Garber, W. Timothy Garvey, Robert R. Henry, Irl B. Hirsch, Edward S. Horton, Daniel L. Hurley, Paul S. Jellinger, Lois Jovanovič, Harold E. Lebovitz, Derek LeRoith, Philip Levy, Janet B. McGill, Jeffrey I. Mechanick, Jorge H. Mestman, Etie S. Moghissi, Eric A. Orzeck, Rachel Pessah-Pollack, Paul D. Rosenblit, Aaron I. Vinik, Kathleen Wyne & Farhad Zangeneh. (2015) American Association Of Clinical Endocrinologists And American College Of Endocrinology -Clinical Practice Guidelines For Developing A Diabetes Mellitus Comprehensive Care Plan – 2015. Endocrine Practice 21, pages 1-87.
Crossref
Crossref
D. Yabe, H. Kuwata, M. Kaneko, C. Ito, R. Nishikino, K. Murorani, T. Kurose & Y. Seino. (2014)
Use of the Japanese health insurance claims database to assess the risk of acute pancreatitis in patients with diabetes: comparison of
DPP
‐4 inhibitors with other oral antidiabetic drugs
. Diabetes, Obesity and Metabolism 17:4, pages 430-434.
Crossref
Crossref
Carlo B. Giorda, Carlotta Sacerdote, Elisa Nada, Lisa Marafetti, Ileana Baldi & Roberto Gnavi. (2014) Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine 48:2, pages 461-471.
Crossref
Crossref
Ricardo Godinho, Cristina Mega, Edite Teixeira-de-Lemos, Eugénia Carvalho, Frederico Teixeira, Rosa Fernandes & Flávio Reis. (2015) The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A “Me Too” or “the Special One” Antidiabetic Class?. Journal of Diabetes Research 2015, pages 1-28.
Crossref
Crossref
T. Wang, F. Wang, Z. Gou, H. Tang, C. Li, L. Shi & S. Zhai. (2015) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies. Diabetes, Obesity and Metabolism 17:1, pages 32-41.
Crossref
Crossref
Joshua J. Neumiller. (2015) Incretin-Based Therapies. Medical Clinics of North America 99:1, pages 107-129.
Crossref
Crossref
M. Gokhale, J. B. Buse, C. L. Gray, V. Pate, M. A. Marquis & T. Stürmer. (2014) Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. Diabetes, Obesity and Metabolism 16:12, pages 1247-1256.
Crossref
Crossref
Hala Ahmadieh & Sami T. Azar. (2014) The role of incretin-based therapies in prediabetes: A review. Primary Care Diabetes 8:4, pages 286-294.
Crossref
Crossref
S. Montilla, G. Marchesini, A. Sammarco, M.P. Trotta, P.D. Siviero, C. Tomino, D. Melchiorri & L. Pani. (2014) Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovascular Diseases 24:12, pages 1346-1353.
Crossref
Crossref
Martin Haluzík, Miloš Mráz & Štěpán Svačina. (2014) Balancing Benefits and Risks in Patients Receiving Incretin-Based Therapies: Focus on Cardiovascular and Pancreatic Side Effects. Drug Safety 37:12, pages 1003-1010.
Crossref
Crossref
Stefan Z Lutz, Harald Staiger, Andreas Fritsche & Hans-Ulrich Häring. (2014) Antihyperglycaemic therapies and cancer risk. Diabetes and Vascular Disease Research 11:6, pages 371-389.
Crossref
Crossref
C. B. Giorda, E. Nada, B. Tartaglino, L. Marafetti & R. Gnavi. (2014) A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes, Obesity and Metabolism 16:11, pages 1041-1047.
Crossref
Crossref
William M. Steinberg, Michael A. Nauck, Bernard Zinman, Gilbert H. Daniels, Richard M. Bergenstal, Johannes F.E. Mann, Lasse Steen Ravn, Alan C. Moses, Mette Stockner, Florian M.M. Baeres, Steven P. Marso & John B. Buse. (2014) LEADER 3—Lipase and Amylase Activity in Subjects With Type 2 Diabetes. Pancreas 43:8, pages 1223-1231.
Crossref
Crossref
Baptist Gallwitz. (2014) Extra-pancreatic effects of incretin-based therapies. Endocrine 47:2, pages 360-371.
Crossref
Crossref
D. Roy, K. D. Chadwick, K. Tatarkiewicz, C. LaCerte, A.-M. Bergholm, T. Brodie, R. S. Mangipudy, D. Parkes, M. J. Graziano & T. P. Reilly. (2014) The glucagon-like peptide-1-based therapeutics exenatide and saxagliptin did not cause detrimental effects on the pancreas in mice, rats, dogs and monkeys. Diabetes, Obesity and Metabolism 16:10, pages 910-921.
Crossref
Crossref
William T. Cefalu, John B. Buse, Stefano Del Prato, Philip D. HomeDerek LeRoith, Michael A. Nauck, Itamar Raz, Julio Rosenstock & Matthew C. Riddle. (2014) Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. Diabetes Care 37:9, pages 2647-2659.
Crossref
Crossref
Itamar Raz, Deepak L. Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M. Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona Buskila, Nayyar Iqbal, Norton Greenberger & Markus M. Lerch. (2014) Incidence of Pancreatitis and Pancreatic Cancer in a Randomized Controlled Multicenter Trial (SAVOR-TIMI 53) of the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin. Diabetes Care 37:9, pages 2435-2441.
Crossref
Crossref
J. Seufert & B. Gallwitz. (2014) The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes, Obesity and Metabolism 16:8, pages 673-688.
Crossref
Crossref
Matthew Nelson, Niyati Bhandari & Jill Wener. (2014) Sitagliptin‐induced pancreatitis – a longer road than expected. Clinical Case Reports 2:4, pages 149-152.
Crossref
Crossref
Hsin-Chun Chou, Wen-Wen Chen & Fei-Yuan Hsiao. (2014) Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study. Drug Safety 37:7, pages 521-528.
Crossref
Crossref
Hejun Zhao, Rui Wei, Liang Wang, Qing Tian, Ming Tao, Jing Ke, Ye Liu, Wenfang Hou, Lin Zhang, Jin Yang & Tianpei Hong. (2014) Activation of glucagon-like peptide-1 receptor inhibits growth and promotes apoptosis of human pancreatic cancer cells in a cAMP-dependent manner. American Journal of Physiology-Endocrinology and Metabolism 306:12, pages E1431-E1441.
Crossref
Crossref
Nathaniel R. SmilowitzRobert DonninoArthur Schwartzbard. (2014) Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus. Circulation 129:22, pages 2305-2312.
Crossref
Crossref
Thomas Karagiannis, Panagiota Boura & Apostolos Tsapas. (2014) Safety of dipeptidyl peptidase 4 inhibitors: a perspective review. Therapeutic Advances in Drug Safety 5:3, pages 138-146.
Crossref
Crossref
Yuanhui Zhang, Rozalina G. McCoy, Jennifer E. Mason, Steven A. Smith, Nilay D. Shah & Brian T. Denton. (2014) Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?. Diabetes Care 37:5, pages 1338-1345.
Crossref
Crossref
Kristina D. Chadwick, Anthony M. Fletcher, M. Cecilia Parrula, Susan Bonner-Weir, Raja S. Mangipudy, Evan Janovitz, Michael J. Graziano, Denis Roy & Timothy P. Reilly. (2014) Occurrence of Spontaneous Pancreatic Lesions in Normal and Diabetic Rats: A Potential Confounding Factor in the Nonclinical Assessment of GLP-1–Based Therapies. Diabetes 63:4, pages 1303-1314.
Crossref
Crossref
Lynley D. Pound, Paul Kievit & Kevin L. Grove. (2014) The nonhuman primate as a model for type 2 diabetes. Current Opinion in Endocrinology, Diabetes & Obesity 21:2, pages 89-94.
Crossref
Crossref
Hanae Ueyama, Shiro Hinotsu, Shiro Tanaka, Hisashi Urushihara, Masaki Nakamura, Yuji Nakamura & Koji Kawakami. (2014) Application of a Self-Controlled Case Series Study to a Database Study in Children. Drug Safety 37:4, pages 259-268.
Crossref
Crossref
Thomas Forest, Daniel Holder, Adam Smith, Caron Cunningham, Xiaorui Yao, Markus Dey, Clay Frederick & Srinivasa Prahalada. (2014) Characterization of the Exocrine Pancreas in the Male Zucker Diabetic Fatty Rat Model of Type 2 Diabetes Mellitus Following 3 Months of Treatment With Sitagliptin. Endocrinology 155:3, pages 783-792.
Crossref
Crossref
Steven E Kahn, Mark E Cooper & Stefano Del Prato. (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. The Lancet 383:9922, pages 1068-1083.
Crossref
Crossref
Paul L. McCormack. (2014) Exenatide Twice Daily: A Review of Its Use in the Management of Patients with Type 2 Diabetes Mellitus. Drugs 74:3, pages 325-351.
Crossref
Crossref
Samuel S. Grossman. (2014) Pathophysiological and Pharmacological Rationale for the Use of Exenatide Once Weekly in Patients with Type 2 Diabetes. Advances in Therapy 31:3, pages 247-263.
Crossref
Crossref
Xiaochun Li, Zuoyi Zhang & Jon Duke. (2014) Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis. Pharmacoepidemiology and Drug Safety 23:3, pages 234-239.
Crossref
Crossref
S. K. Garg, H. Maurer, K. Reed & R. Selagamsetty. (2013) Diabetes and cancer: two diseases with obesity as a common risk factor. Diabetes, Obesity and Metabolism 16:2, pages 97-110.
Crossref
Crossref
Mark E. Williams & Rajesh Garg. (2014) Glycemic Management in ESRD and Earlier Stages of CKD. American Journal of Kidney Diseases 63:2, pages S22-S38.
Crossref
Crossref
Matteo Monami, Ilaria Dicembrini, Camilla Nardini, Irene Fiordelli & Edoardo Mannucci. (2014) Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes Research and Clinical Practice 103:2, pages 269-275.
Crossref
Crossref
Carlo B Giorda, Roberta Picariello, Elisa Nada, Barbara Tartaglino, Lisa Marafetti, Giuseppe Costa & Roberto Gnavi. (2014) Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. The Lancet Diabetes & Endocrinology 2:2, pages 111-115.
Crossref
Crossref
Greg L. Plosker. (2014) Sitagliptin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:2, pages 223-242.
Crossref
Crossref
LathaSubramanya Moodahadu, Ruchi Dhall, Sudhakar Banġera, Ramesh Katipally, AbdulHamid Zarġar & Lalitha Ramani. (2014) Tight glycemic control and cardiovascular effects in type 2 diabetic patients. Heart Views 15:4, pages 111.
Crossref
Crossref
Mark P Plummer, Marianne J Chapman, Michael Horowitz & Adam M Deane. (2014) Incretins and the intensivist: what are they and what does an intensivist need to know about them?. Critical Care 18:1, pages 205.
Crossref
Crossref
M. Monami, I. Dicembrini & E. Mannucci. (2014) Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes, Obesity and Metabolism 16:1, pages 48-56.
Crossref
Crossref
Marc van den Heever, Anubhav Mittal, Matthew Haydock & John Windsor. (2014) The use of intelligent database systems in acute pancreatitis – A systematic review. Pancreatology 14:1, pages 9-16.
Crossref
Crossref
Jean-Luc Faillie, Samy Babai, Sabrina Crépin, Virginie Bres, Marie-Laure Laroche, Hervé Le Louet, Pierre Petit, Jean-Louis Montastruc & Dominique Hillaire-Buys. (2013) Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. Acta Diabetologica.
Crossref
Crossref
Carlos Alves, Ana Filipa Macedo & Francisco Batel Marques. (2013) Sources of information used by regulatory agencies on the generation of drug safety alerts. European Journal of Clinical Pharmacology 69:12, pages 2083-2094.
Crossref
Crossref
German Ramirez, Anthony D. Morrison & Polly A. Bittle. (2013) Clinical Practice Considerations and Review of the Literature for the Use of DPP-4 Inhibitors in Patients with Type 2 Diabetes and Chronic Kidney Disease. Endocrine Practice 19:6, pages 1025-1034.
Crossref
Crossref
Jaime A. Davidson. (2013) The Placement of DPP-4 Inhibitors in Clinical Practice Recommendations for the Treatment of Types 2 Diabetes. Endocrine Practice 19:6, pages 1050-1061.
Crossref
Crossref
Harold E. Lebovitz. (2013) Incretin-Based Therapies: Facing the Realities of Benefits Versus Side Effects. Diabetes Technology & Therapeutics 15:11, pages 909-913.
Crossref
Crossref
Timothy S. Reid. (2013) Practical Use of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Primary Care. Clinical Diabetes 31:4, pages 148-157.
Crossref
Crossref
C. Wysham, M. Grimm & S. Chen. (2013) Once weekly exenatide: efficacy, tolerability and place in therapy. Diabetes, Obesity and Metabolism 15:10, pages 871-881.
Crossref
Crossref
R. E. J. Ryder. (2013) The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits. Diabetic Medicine 30:10, pages 1148-1155.
Crossref
Crossref
Fei Xue, Haijun Ma, Catherine Stehman‐Breen, Christine Haller, Leonid Katz, Rachel B. Wagman & Cathy W. Critchlow. (2013)
Design and methods of a postmarketing pharmacoepidemiology study assessing long‐term safety of Prolia
®
(denosumab) for the treatment of postmenopausal osteoporosis
. Pharmacoepidemiology and Drug Safety 22:10, pages 1107-1114.
Crossref
Crossref
Bo Ahrén. (2013) GLP-1 receptor agonists in the treatment of Type 2 diabetes. Diabetes Management 3:5, pages 401-413.
Crossref
Crossref
Kathryn Aston-Mourney, Shoba L. SubramanianSakeneh ZraikaThanya SamarasekeraDaniel T. MeierLynn C. Goldstein & Rebecca L. Hull. (2013) One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice. American Journal of Physiology-Endocrinology and Metabolism 305:4, pages E475-E484.
Crossref
Crossref
Michael A. Nauck & Nele Friedrich. (2013) Do GLP-1–Based Therapies Increase Cancer Risk?. Diabetes Care 36:Supplement_2, pages S245-S252.
Crossref
Crossref
E. Raschi, C. Piccinni, E. Poluzzi, G. Marchesini & F. De Ponti. (2011) The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica 50:4, pages 569-577.
Crossref
Crossref
Yehuda Handelsman, Derek LeRoith, Zachary T. Bloomgarden, Samuel Dagogo-Jack, Daniel Einhorn, Alan J. Garber, George Grunberger, R. Mack Harrell, Robert F. Gagel, Harold E. Lebovitz, Janet B. McGill & Charles H. Hennekens. (2013) Diabetes and Cancer—An AACE/ACE Consensus Statement. Endocrine Practice 19:4, pages 675-693.
Crossref
Crossref
Clifford J. Bailey. (2013) Interpreting Adverse Signals in Diabetes Drug Development Programs. Diabetes Care 36:7, pages 2098-2106.
Crossref
Crossref
Peter C. Butler, Michael Elashoff, Robert Elashoff & Edwin A.M. Gale. (2013) A Critical Analysis of the Clinical Use of Incretin-Based Therapies. Diabetes Care 36:7, pages 2118-2125.
Crossref
Crossref
Michael A. Nauck. (2013) A Critical Analysis of the Clinical Use of Incretin-Based Therapies. Diabetes Care 36:7, pages 2126-2132.
Crossref
Crossref
Baptist Gallwitz. (2013) Incretin for the continuing treatment of secondary failure to metformin in Type 2 diabetes. Diabetes Management 3:4, pages 323-331.
Crossref
Crossref
Baptist Gallwitz. (2013) Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors. Therapeutic Advances in Endocrinology and Metabolism 4:3, pages 95-105.
Crossref
Crossref
R. Balena, I. E. Hensley, S. Miller & A. H. Barnett. (2012)
Combination therapy with
GLP
‐1 receptor agonists and basal insulin: a systematic review of the literature
. Diabetes, Obesity and Metabolism 15:6, pages 485-502.
Crossref
Crossref
Hirotake Tokuyama, Harukiyo Kawamura, Masaki Fujimoto, Kazuki Kobayashi, Mie Nieda, Tetsuya Okazawa, Minoru Takemoto & Fumio Shimada. (2013) A low-grade increase of serum pancreatic exocrine enzyme levels by dipeptidyl peptidase-4 inhibitor in patients with type 2 diabetes. Diabetes Research and Clinical Practice 100:3, pages e66-e69.
Crossref
Crossref
Jonathan E. Campbell & Daniel J. Drucker. (2013) Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action. Cell Metabolism 17:6, pages 819-837.
Crossref
Crossref
Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman & Barry J. Goldstein. (2013) Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies. Diabetes Therapy 4:1, pages 119-145.
Crossref
Crossref
Jeff Unger, Debbie Hinnen, Barbara Schreiner & Chris Parkin. (2013) Putting medications where they belong: Practical advice for managing type 2 diabetes in clinical practice. Journal of the American Academy of Nurse Practitioners 25:2, pages 65-76.
Crossref
Crossref
Linde M. Morsink, Mark M. Smits & Michaela Diamant. (2013) Advances in Pharmacologic Therapies for Type 2 Diabetes. Current Atherosclerosis Reports 15:2.
Crossref
Crossref
Mariko SueAya YoshiharaKoji KubokiNaoki HiroiGen Yoshino. (2013) A Case of Severe Acute Necrotizing Pancreatitis after Administration of Sitagliptin. Clinical Medicine Insights: Case Reports 6, pages CCRep.S10856.
Crossref
Crossref
Eun-Hee Cho. (2013) Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis. The Journal of Korean Diabetes 14:3, pages 138.
Crossref
Crossref
Nam Hoon KimSin Gon Kim. (2013) Comparison of DPP-4 Inhibitors. The Journal of Korean Diabetes 14:3, pages 111.
Crossref
Crossref
James R. LaSalle. (2013) Enhancing treatment success with incretin-based therapies: A comprehensive approach to the patient with diabetes. Osteopathic Family Physician 5:1, pages 51-57.
Crossref
Crossref
Hisashi Urushihara, Masanori Taketsuna, Ying Liu, Eisei Oda, Masaki Nakamura, Shinichi Nishiuma & Rei Maeda. (2012) Increased Risk of Acute Pancreatitis in Patients with Type 2 Diabetes: An Observational Study Using a Japanese Hospital Database. PLoS ONE 7:12, pages e53224.
Crossref
Crossref
Paea LePendu, Srinivasan V Iyer, Cédrick Fairon & Nigam H Shah. (2012) Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. Journal of Biomedical Semantics 3:S1.
Crossref
Crossref
Michael Cobble. (2012) Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus. Diabetology & Metabolic Syndrome 4:1.
Crossref
Crossref
K. Gooßen & S. Gräber. (2012) Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis. Diabetes, Obesity and Metabolism 14:12, pages 1061-1072.
Crossref
Crossref
Ajay Kumar. (2012)
Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors
versus
sulphonylurea/insulin: For GLP-1/DPP-IV inhibitors
. Diabetes/Metabolism Research and Reviews 28, pages 21-25.
Crossref
Crossref
Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber & Carol H. Wysham. (2012) Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice 18, pages 6-26.
Crossref
Crossref
H.‐N. Shen, Y.‐H. Chang, H.‐F. Chen, C.‐L. Lu & C.‐Y. Li. (2012) Increased risk of severe acute pancreatitis in patients with diabetes. Diabetic Medicine 29:11, pages 1419-1424.
Crossref
Crossref
M. Wenten, J. A. Gaebler, M. Hussein, E. M. Pelletier, D. B. Smith, P. Girase, R. A. Noel, D. K. Braun & G. L. Bloomgren. (2012) Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti‐diabetic medication: a follow‐up study. Diabetic Medicine 29:11, pages 1412-1418.
Crossref
Crossref
Carlos Alves, Francisco Batel-Marques & Ana F. Macedo. (2012) A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer. Diabetes Research and Clinical Practice 98:2, pages 271-284.
Crossref
Crossref
John A. RomleyDana P. GoldmanMatthew SolomonDaniel McFaddenAnne L. Peters. (2012) Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population. Diabetes Technology & Therapeutics 14:10, pages 904-911.
Crossref
Crossref
Leshuai W. Zhang, Grainne A. McMahon Tobin & Rodney L. Rouse. (2012) Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line. Toxicology and Applied Pharmacology 264:2, pages 274-283.
Crossref
Crossref
Yuzheng Xue, Yingyue Sheng, Hong Dai, Haiyan Cao, Zongliang Liu & Zhaoshen Li. (2012) Risk of development of acute pancreatitis with pre-existing diabetes. European Journal of Gastroenterology & Hepatology 24:9, pages 1092-1098.
Crossref
Crossref
Young Min Cho, Catherine E. Merchant & Timothy J. Kieffer. (2012) Targeting the glucagon receptor family for diabetes and obesity therapy. Pharmacology & Therapeutics 135:3, pages 247-278.
Crossref
Crossref
David D. Dore, John D. Seeger & K. Arnold Chan. (2012) Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. Therapeutic Advances in Drug Safety 3:4, pages 157-164.
Crossref
Crossref
R. Gomis, D. R. Owens, M.-R. Taskinen, S. Del Prato, S. Patel, A. Pivovarova, A. Schlosser & H.-J. Woerle. (2012) Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice 66:8, pages 731-740.
Crossref
Crossref
M.S. Fineman, B.B. Cirincione, D. Maggs & M. Diamant. (2012) GLP‐1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism 14:8, pages 675-688.
Crossref
Crossref
Niels VrangJacob JelsingLotte Simonsen, Andres Eskjær JensenInger Thorup, Henrik Søeborg & Lotte Bjerre Knudsen. (2012) The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. American Journal of Physiology-Endocrinology and Metabolism 303:2, pages E253-E264.
Crossref
Crossref
Howard M. Lando, May Alattar & Anuradha P. Dua. (2012) Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors In the Outpatient Setting. Endocrine Practice 18:4, pages 472-477.
Crossref
Crossref
N. H. Shah & J. D. Tenenbaum. (2012) The coming age of data-driven medicine: translational bioinformatics' next frontier. Journal of the American Medical Informatics Association 19:e1, pages e2-e4.
Crossref
Crossref
Niels C.B. Nyborg, Anne-Marie Mølck, Lars W. Madsen & Lotte Bjerre Knudsen. (2012) The Human GLP-1 Analog Liraglutide and the Pancreas. Diabetes 61:5, pages 1243-1249.
Crossref
Crossref
Peter M. Wahl, Joshua J. Gagne, Thomas E. Wasser, Debra F. Eisenberg, J. Keith Rodgers, Gregory W. Daniel, Marcus Wilson, Sebastian Schneeweiss, Jeremy A. Rassen, Amanda R. Patrick, Jerry Avorn & Rhonda L. Bohn. (2012) Early Steps in the Development of a Claims-Based Targeted Healthcare Safety Monitoring System and Application to Three Empirical Examples. Drug Safety 35:5, pages 407-416.
Crossref
Crossref
G. Schernthaner, A. H. Barnett, A. Emser, S. Patel, J. Troost, H.‐J. Woerle & M. von Eynatten. (2012) Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 14:5, pages 470-478.
Crossref
Crossref
Nicholas S. Solanki, Savio G. Barreto & Gino T.P. Saccone. (2012) Acute pancreatitis due to diabetes: The role of hyperglycaemia and insulin resistance. Pancreatology 12:3, pages 234-239.
Crossref
Crossref
L. Blonde & E. Montanya. (2012) Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes, Obesity and Metabolism 14, pages 20-32.
Crossref
Crossref
Sten Madsbad. (2012) Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No. European Journal of Internal Medicine 23:2, pages 132-136.
Crossref
Crossref
R. E. van Genugten, D. H. van Raalte & M. Diamant. (2011) Dipeptidyl peptidase‐4 inhibitors and preservation of pancreatic islet‐cell function: a critical appraisal of the evidence. Diabetes, Obesity and Metabolism 14:2, pages 101-111.
Crossref
Crossref
Raluca Ionescu-Ittu, Michal Abrahamowicz & Louise Pilote. (2012) Treatment effect estimates varied depending on the definition of the provider prescribing preference-based instrumental variables. Journal of Clinical Epidemiology 65:2, pages 155-162.
Crossref
Crossref
Amir Hanna, Vincent Woo, Jean-François Yale & Elaine M. Cooke. (2012) Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes. Canadian Journal of Diabetes 36:1, pages 9-14.
Crossref
Crossref
Shridhar N. Iyer, Almond J. DrakeIIIIII, R. Lee West, Carlos E. Mendez & Robert J. Tanenberg. (2012) Case Report of Acute Necrotizing Pancreatitis Associated with Combination Treatment of Sitagliptin and Exenatide. Endocrine Practice 18:1, pages e10-e13.
Crossref
Crossref
Rupa Ahluwalia & Jiten Vora. (2012) Safety and tolerability of glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes. The British Journal of Diabetes & Vascular Disease 12:1, pages 6-16.
Crossref
Crossref
Dominique Xavier Brown & Marc Evans. (2012) Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective. Journal of Nutrition and Metabolism 2012, pages 1-10.
Crossref
Crossref
Kevin Moores, Bradley Gilchrist, Ryan Carnahan & Thad Abrams. (2012) A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiology and Drug Safety 21, pages 194-202.
Crossref
Crossref
Joshua J. Gagne, Bruce Fireman, Patrick B. Ryan, Malcolm Maclure, Tobias Gerhard, Sengwee Toh, Jeremy A. Rassen, Jennifer C. Nelson & Sebastian Schneeweiss. (2012) Design considerations in an active medical product safety monitoring system. Pharmacoepidemiology and Drug Safety 21, pages 32-40.
Crossref
Crossref
Nobuya Inagaki, Kohjiro Ueki, Ayuko Yamamura, Hitoshi Saito & Takeshi Imaoka. (2011) Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes. Journal of Diabetes Investigation 2:6, pages 448-456.
Crossref
Crossref
Liza K. Phillips & Johannes B. Prins. (2011) Update on incretin hormones. Annals of the New York Academy of Sciences 1243:1, pages E55-E74.
Crossref
Crossref
Zachary T. Bloomgarden. (2011) American Diabetes Association Postgraduate Meetings—2011. Diabetes Care 34:11, pages e164-e169.
Crossref
Crossref
Kathleen R. Richard, Jamie S. Shelburne & Julienne K. Kirk. (2011) Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review. Clinical Therapeutics 33:11, pages 1609-1629.
Crossref
Crossref
William J. Valentine, Andrew J. Palmer, Morten Lammert, Jakob Langer & Michael Brändle. (2011) Evaluating the Long-Term Cost-Effectiveness of Liraglutide Versus Exenatide BID in Patients With Type 2 Diabetes Who Fail to Improve With Oral Antidiabetic Agents. Clinical Therapeutics 33:11, pages 1698-1712.
Crossref
Crossref
Baptist Gallwitz. (2011) Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus. Drugs 71:13, pages 1675-1688.
Crossref
Crossref
William M Steinberg. (2011) Comment: Acute Pancreatitis Associated with Liraglutide. Annals of Pharmacotherapy 45:9, pages 1169-1169.
Crossref
Crossref
Scott V. Joy, Jeffrey S. Freeman & James R. LaSalle. (2011) Tailoring treatment for type 2 diabetes: Uncovering the HOW and NOW of GLP-1 receptor agonist therapy. Osteopathic Family Physician 3:5, pages 217-236.
Crossref
Crossref
Enric Esmatjes Mompó. (2011) Seguridad de los fármacos basados en incretinas. Avances en Diabetología 27:5, pages 151-153.
Crossref
Crossref
Vanita R. Aroda & Robert Ratner. (2011) The safety and tolerability of GLP‐1 receptor agonists in the treatment of type 2 diabetes: a review. Diabetes/Metabolism Research and Reviews 27:6, pages 528-542.
Crossref
Crossref
Joachim Spranger, Ursula Gundert–Remy & Thomas Stammschulte. (2011) GLP-1–Based Therapies: The Dilemma of Uncertainty. Gastroenterology 141:1, pages 20-23.
Crossref
Crossref
Displaying 200 of 259 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list